This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Elsevier And PMPH To Co-Publish China's Former Minister Of Health Chen Zhu's Book On Health Reforms In China

BEIJING, June 9, 2014 /PRNewswire/ --

English translation of book, "Healthy China 2020 Strategic Research Report", will make documentation of China's medical and healthcare reforms widely available and accessible for   reference around the world  

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, and People's Medical Publishing House (PMPH), China, announced today their agreement to jointly-publish the English edition of Healthy China 2020 Strategic Research Report by China's former Minister of Health, Chen Zhu, who served as editor-in-chief on the book.

Published by PMPH in Chinese in August 2012, Healthy China 2020 Strategic Research Report details China's health reforms over the last 60 years. It includes candid discussions on the major health issues and challenges faced by the country as well as a comprehensive look at the strategic priorities, development goals and practical policy recommendations to take China's healthcare system forward into the future.

"With the advancement of healthcare reforms in China, we have to proactively address increasingly complex issues and concerns", said Dr. Chen, now Vice-Chairman of the National People's Congress, China. "That will require better coordination amongst the relevant governmental departments to shift the focus from disease diagnosis and treatment to prevention and control, establishing robust public funding mechanisms, reducing individual contribution to health care expenses as well as integrating the health care systems from both urban and rural regions."

"We are glad for this opportunity to co-publish Dr. Chen's book in English with Elsevier and introduce it to the rest of world," said Mr. Chen Xianyi, President of PMPH. "Elsevier has an outstanding reputation as a global publisher and information provider, and we believe that working with Elsevier will help distribute the information contained in this book to places where it's needed."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,081.89 -49.97 -0.29%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,796.6090 -42.0340 -0.87%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs